Authors

Walter Rayford, The Urology Group LLC
Alp Tuna Beksac, Icahn School of Medicine at Mount Sinai,
Jordan Alger, Medstar Georgetown University Hospital
Mohammed Alshalalfa, University of California San Francisco
Mohsen Ahmed, Icahn School of Medicine at Mount Sinai
Irtaza Khan, Icahn School of Medicine at Mount Sinai
Ugo G. Falagario, Icahn School of Medicine at Mount Sinai
Yang Liu, Decipher Biosciences
Elai Davicioni, Decipher Biosciences
Daniel E. Spratt, University of Michigan
Edward M. Schaeffer, Northwestern University
Felix Y. Feng, University of California San Francisco
Brandon Mahal, Brigham and Women's Hospital
Paul L Nguyen, Brigham and Women's Hospital
Robert B. Den, Thomas Jefferson UniversityFollow
Mark D. Greenberger, The Urology Group LLC
Randy Bradley, University of Tennessee, Knoxville
Justin M. Watson, WellStar Urology
Matthew Beamer, Medstar Georgetown University Hospital
Lambros Stamatakis, Medstar Georgetown University Hospital
Darrell J. Carmen, Georgia Urology
Shivanshu Awasthi, Moffitt Cancer Center
Jonathan Hwang, Medstar Georgetown University Hospital
Rachel Weil, Icahn School of Medicine at Mount Sinai
Harri Merisaari, University of Turku
Nihal Mohamed, Icahn School of Medicine at Mount Sinai
Leslie A. Deane, Rush University Medical Center
Dimple Chakravarty, Icahn School of Medicine at Mount Sinai
Kamlesh K. Yadav, Sema4
Kosj Yamoah, Moffitt Cancer Center
Sujit S. Nair, Icahn School of Medicine at Mount Sinai
Ashutosh K. Tewari, Icahn School of Medicine at Mount Sinai

Document Type

Article

Publication Date

6-3-2021

Comments

This article is the authors’ final published version in Communications Biology, Volume 4, Issue 1, June 2021, Article number 670.

The published version is available at https://doi.org/10.1038/s42003-021-02140-y. Copyright © Rayford et al.

Abstract

Racial disparities in prostate cancer have not been well characterized on a genomic level. Here we show the results of a multi-institutional retrospective analysis of 1,152 patients (596 African-American men (AAM) and 556 European-American men (EAM)) who underwent radical prostatectomy. Comparative analyses between the race groups were conducted at the clinical, genomic, pathway, molecular subtype, and prognostic levels. The EAM group had increased ERG (P < 0.001) and ETS (P = 0.02) expression, decreased SPINK1 expression (P < 0.001), and basal-like (P < 0.001) molecular subtypes. After adjusting for confounders, the AAM group was associated with higher expression of CRYBB2, GSTM3, and inflammation genes (IL33, IFNG, CCL4, CD3, ICOSLG), and lower expression of mismatch repair genes (MSH2, MSH6) (p < 0.001 for all). At the pathway level, the AAM group had higher expression of genes sets related to the immune response, apoptosis, hypoxia, and reactive oxygen species. EAM group was associated with higher levels of fatty acid metabolism, DNA repair, and WNT/beta-catenin signaling. Based on cell lines data, AAM were predicted to have higher potential response to DNA damage. In conclusion, biological characteristics of prostate tumor were substantially different in AAM when compared to EAM.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

PubMed ID

34083737

Language

English

Share

COinS